Regulatorysemaglutidetirzepatideliraglutidefaerspharmacovigilance

FAERS analysis flags muscle atrophy signal for semaglutide and tirzepatide

Disproportionality was strongest for semaglutide, with a reporting odds ratio of 3.96 across 182 reports, and persisted in serious-report analyses.

By Daniel Okafor · Regulatory Correspondent

Sep 21 20:00 ETSource: Cureus

The wire

01Researchers screened 20,006,989 FAERS reports through Jan. 27, 2026, finding eight signals across semaglutide, liraglutide and tirzepatide; muscle atrophy led with ROR 3.96 for semaglutide and 2.29 for tirzepatide.
02Lower-magnitude signals included back pain, muscle spasms and neck pain for semaglutide, and back pain, osteoarthritis and neck pain for liraglutide, relevant to clinicians monitoring lean-mass loss.
03The authors state the data cannot show causation or incidence among treated patients; spontaneous reporting is subject to bias and prospective studies are needed.

From the source

Musculoskeletal Adverse Event Signals Associated With Semaglutide, Liraglutide, and Tirzepatide in the US FDA Adverse Event Reporting System
Cureus · 2026 Sep · Wadhwa A, Patel D, Bouras A et al.

Read at pubmed.ncbi.nlm.nih.gov

Source URL https://pubmed.ncbi.nlm.nih.gov/42921281/